It is important to resolve this discrepancy considering that insoluble tau aggregates are more closely associated with neurodegeneration and cognitive impairment in AD11 and efficient immunomodulatory therapies will probably need to affect the accumulation of tau aggregates to provide a robust clinical benefit. The gene discussed is MAPT; the disease is Cognitive impairment.